BioWorld

June 18, 2007

Lpath Moving Sphingomab Into Clinic With $16.8M Financing

Lpath Inc. closed the second tranche of an April private placement, for a total financing of $16.8 million to push its lead compound, the anti-angiogenic compound Sphingomab, into the clinic.(BioWorld Today) Read More

TransOral Reports Positive Data From Phase III Trial In Insomnia

Analyst Opinion Divided On La Jolla's Riquent For Lupus

NewCo News: Tempo Hurries To Target Nanoparticle Combo Drugs

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 4, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

EASL 2026: Emerging liver disease targets to watch

BioWorld

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...